Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cempra Completes Enrollment In Phase 2 Taksta Trial
The phase 2/3 trial uses an adaptive-design in which the phase 2 portion enrolled 180 patients with acute cellulitis or wound infections into one of the three arms:
The phase 2/3 trial uses an adaptive-design in which the phase 2 portion enrolled 180 patients with acute cellulitis or wound infections into one of the three arms:
The study evaluated the safety, tolerability, and pharmacokinetics of repeated doses of intravenously administered antibody in 24 rheumatoid arthritis patients with an inadequate treatment response to methotrexate. The
The randomized, double-blind, placebo-controlled, dose-escalation trial is expected to enroll 135 patients and will be conducted in multiple centers in several European countries. Patients with active RA, despite
The study, ‘New Technologies for Cervical Cancer (NTCC)’ assessed the benefits and risks of shifting to HPV testing from standard cytology (Pap testing) in cervical cancer screening programs
Atul Sobti, MD and CEO of Ranbaxy, said: “With an increasing focus on prevention of disease, the importance of the vaccine market has never been greater. This transaction
The secondary objective of the trial also monitored the injected tumour and other distant tumours for signs of Cavatak activity against actively progressing metastatic melanoma. Injected tumours of
The Intercept device is the FDA-cleared in vitro diagnostic laboratory-based oral fluid testing system used for detecting commonly abused drugs such as marijuana, cocaine, opiates, PCP and amphetamines
The company said that in cat allergy trial 210 patients are expected to be randomised to receive placebo or one of two regimes of the company’s T-cell vaccine.
The latest funding round includes £315,000 equity investment from Finance Wales and a £147,000 grant from the Welsh Assembly Government’s Single Investment Fund. It will allow the company
The oral fluid assays use Roche’s KIMS (kinetic interaction of micro-particles in solution) technology and are being jointly developed under an agreement previously signed by the parties. The